Cover Image
市場調查報告書

B細胞非何杰金氏淋巴瘤 (NHL) - 機會分析與預測

OpportunityAnalyzer: B-Cell Non-Hodgkin's Lymphoma (NHL) - Opportunity Analysis and Forecasts to 2024

出版商 GlobalData 商品編碼 355915
出版日期 內容資訊 英文 282 Pages
訂單完成後即時交付
價格
Back to Top
B細胞非何杰金氏淋巴瘤 (NHL) - 機會分析與預測 OpportunityAnalyzer: B-Cell Non-Hodgkin's Lymphoma (NHL) - Opportunity Analysis and Forecasts to 2024
出版日期: 2016年01月01日 內容資訊: 英文 282 Pages
簡介

全球7大市場非何杰金氏淋巴瘤市場,預計從2014年的48億2,000萬美元以年複合成長率1.0%擴大,2024年略低於55億美元的規模。隨著DLBCL的一次及復發/難治性疾病的高價藥Imbruvica的上市,複合適應症的Revlimid預定上市,加速市場擴大。

本報告提供全球B細胞非何杰金氏淋巴瘤 (NHL) 市場相關調查,市場未滿足需求,企業的研究開發策略,開發平台趨勢,歐美及日本等各地區趨勢,今後的預測,及打入市場的主要企業簡介等彙整資料。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因及病理學
  • 症狀

第4章 疾病管理

  • 診斷
  • 診斷的時候的分類
  • 治療概要

第5章 流行病學

  • 疾病的背景
  • 風險因素和合併症
  • 全球的趨勢
    • 美國
    • 歐洲5個國家
    • 日本
  • 預測方法
  • B細胞非何杰金氏淋巴瘤的流行病學的預測
  • 考察

第6章 目前治療方法

  • 概要
  • 產品簡介:主力品牌

第7章 未滿足需求評估與機會分析

  • 概要
  • 未滿足需求分析
  • 機會分析

第8章 研究開發策略

  • 概要
  • 臨床實驗設計

第9章 開發平台評估

  • 概要
  • 臨床開發的潛力藥物
  • 創新的早期方法

第10章 開發平台價值分析

  • 主要開發平台藥物的臨床性基準
  • 主要開發平台藥物的商業性基準
  • 競爭評估
  • top line:10年預測

第11章 附錄

圖表

目錄
Product Code: GDHC018POA

Non-Hodgkin's lymphoma (NHL) comprises a heterogeneous group of lymphoproliferative malignancies that arise in the B cells, T cells, or natural killer (NK) cells within the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen. NHLs are further categorized into indolent or aggressive prognostic subtypes, which further influence the outcomes and treatment decisions. Patients diagnosed with indolent NHLs (follicular lymphoma [FL] or marginal zone lymphoma [MZL]) can achieve a median survival of 10 to 20 years, and relative 10-year survival rates of over 60%. However, patients with aggressive NHLs (diffuse large B-cell lymphoma [DLBCL] or mantle cell lymphoma [MCL]) can generally expect lower median survival rates, with the relative 10-year survival reported to be less than 50%.

For the purposes of this report, GlobalData focuses on the four most prevalent B-cell NHL subtypes: FL, MZL, DLBCL and MCL. The global market is defined to include sales of drugs aimed at treatment of those four subtypes in patients 30 years and older across the 7MM, which is comprised of the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan. The forecast includes the sale of agents in first-line, relapsed/refractory, and maintenance settings. GlobalData anticipates a major driver of market growth to be the steady increase in uptake of Imbruvica to treat MCL, and its anticipated expansion into FL, MZL, and DLBCL treatment settings over the forecast period.

Highlights

Key Questions Answered

  • Based on interviews with key opinion leaders (KOLs), GlobalData has identified the major unmet needs in the NHL marketplace. Will the leading pipeline agents fulfil these unmet needs during the forecast period (2014-2024)?
  • What research and development (R&D) strategies will companies leverage to compete in the future NHL marketplace?
  • Which pipeline products are poised to make a major clinical and commercial impact?
  • What clinical and commercial factors are likely to influence NHL drug uptake in the US and 5EU (France, Germany, Italy, Spain, and the UK) and Japan (7MM)?

Key Findings

  • GlobalData projects the NHL market in the 7MM to experience modest growth from approximately $4.82bn in 2014 to a little under $5.5bn in 2024, at a compound annual growth rate (CAGR) of 1.0%. This growth will be fueled by the launch of the premium-priced drug Imbruvica in the DLBCL first-line and relapsed/refractory settings. In addition Revlimid is expected to launch in multiple indications across indolent and aggressive NHL, along with Zydelig, Gazyva, and other novel pipeline products.
  • Primary and secondary research indicates that Imbruvica and Revlimid will experience rapid uptake due to high KOL enthusiasm and promising clinical efficacy results reported thus far. Furthermore, the ability to combine these agents with standard backbone therapies will aid in their uptake.
  • GlobalData anticipates the launch of generic bendamustine and generic lenalidomide, along with biosimilar rituximab, at various times in the different markets during the forecast period. The arrival of those products, in combination with the stringent pricing and reimbursement criteria in the 5EU, will act as major barriers to global NHL market growth.

Scope

  • Overview of NHL, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.
  • Topline NHL drug market revenue from 2014-2024. Annual cost of therapy (ACOT) and major product sales in first-line, relapsed/refractory, and maintenance treatment settings during the forecast period are included.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, opportunities, and R&D strategies for the NHL market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.
  • Analysis of the current and future market competition in the global NHL market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global NHL therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the NHL market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Pathophysiology of Indolent and Aggressive B-Cell NHL
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis
  • 4.2. Diagnostic Classification
    • 4.2.1. Follicular Lymphoma
    • 4.2.2. Marginal Zone Lymphoma
    • 4.2.3. Diffuse Large B-Cell Lymphoma
    • 4.2.4. Mantle Cell Lymphoma
  • 4.3. Treatment Overview
    • 4.3.1. Follicular Lymphoma
    • 4.3.2. Marginal Zone Lymphoma
    • 4.3.3. Diffuse Large B-Cell Lymphoma
    • 4.3.4. Mantle Cell Lymphoma

5. Epidemiology

  • 5.1. Disease Background
  • 5.2. Risk Factors and Comorbidities
  • 5.3. Global Trends
    • 5.3.1. US
    • 5.3.2. 5EU
    • 5.3.3. Japan
  • 5.4. Forecast Methodology
    • 5.4.1. Sources Used
    • 5.4.2. Sources Not Used
    • 5.4.3. Forecast Assumptions and Methods
  • 5.5. Epidemiological Forecast for B-Cell NHL (2014-2024)
    • 5.5.1. Follicular Lymphoma
    • 5.5.2. Marginal Zone Lymphoma
    • 5.5.3. Diffuse Large B-Cell Lymphoma
    • 5.5.4. Mantle Cell Lymphoma
  • 5.6. Discussion
    • 5.6.1. Epidemiological Forecast Insight
    • 5.6.2. Limitations of the Analysis
    • 5.6.3. Strengths of the Analysis

6. Current Treatment Options

  • 6.1. Overview
  • 6.2. Product Profiles - Major Brands
    • 6.2.1. Imbruvica (ibrutinib)
    • 6.2.2. Revlimid (lenalidomide)
    • 6.2.3. Rituxan (rituximab)
    • 6.2.4. Treanda (bendamustine)
    • 6.2.5. Velcade (bortezomib)
    • 6.2.6. Zevalin (ibritumomab tiuxetan)
    • 6.2.7. Zydelig (idelalisib, GS-1101, CAL-101)

7. Unmet Needs Assessment and Opportunity Analysis

  • 7.1. Overview
  • 7.2. Unmet Needs Analysis
    • 7.2.1. Unmet Need: Therapies That Prolong OS or PFS and Delay Relapse in Indolent NHL Patients
    • 7.2.2. Unmet Need: Safe and More Tolerable Front-Line Agents for Indolent NHL Patients
    • 7.2.3. Unmet Need: Prolonged Survival Rates for MCL Patients
    • 7.2.4. Unmet Need: Improved Cure Rate and Survival for DLBCL Patients after Front-Line Therapy
    • 7.2.5. Unmet Need: Predictive and Prognostic Molecular Biomarkers
  • 7.3. Opportunity Analysis
    • 7.3.1. Opportunity: More Cost-Effective Therapies
    • 7.3.2. Opportunity: Improved Consolidation/Maintenance Therapies for Follicular NHL Patients
    • 7.3.3. Opportunity: Novel Agents for Front-Line DLBCL and MCL Therapy
    • 7.3.4. Opportunity: Development of Novel Therapies for NHL Patients

8. Research and Development Strategies

  • 8.1. Overview
    • 8.1.1. Targeting Multiple NHL Subtypes and Lines of Therapy to Capture the Greatest Patient Share
    • 8.1.2. Inhibiting New Targets in Relapsed/Refractory NHL Patients
    • 8.1.3. Novel Approaches to NHL Treatment
    • 8.1.4. Developing Novel Drugs in Combination with Rituxan to Replace Chemoimmunotherapy Regimens
    • 8.1.5. Developing Second-Generation Therapies to Replace the Established Standards of Care at the End of Patent Life
    • 8.1.6. Companies Collaborating on Investigator-Sponsored, Early-Stage Trials to Minimize Up-Front Risk
    • 8.1.7. Introducing New Routes of Drug Delivery to Improve Patient Convenience
  • 8.2. Clinical Trial Design
    • 8.2.1. Indolent and Aggressive B-Cell NHL
    • 8.2.2. Clinical Endpoints
    • 8.2.3. Comparator Arms

9. Pipeline Assessment

  • 9.1. Overview
  • 9.2. Promising Drugs in Clinical Development
    • 9.2.1. Afinitor (everolimus)
    • 9.2.2. Arzerra (ofatumumab)
    • 9.2.3. Copanlisib (BAY 80-6946)
    • 9.2.4. Duvelisib (IPI-145)
    • 9.2.5. Gazyva (obinutuxumab)
    • 9.2.6. Opdivo (nivolumab)
  • 9.3. Innovative Early-Stage Approaches
    • 9.3.1. Adcetris (brentuximab vedotin)
    • 9.3.2. Blinatumomab (AMG-103)
    • 9.3.3. CUDC-907
    • 9.3.4. Daratumumab
    • 9.3.5. Kyprolis (carfilzomib)
    • 9.3.6. Y-90 Epratuzumab
    • 9.3.7. Chimeric Antigen Receptor T-Cell Therapies

10. Pipeline Valuation Analysis

  • 10.1. Clinical Benchmarking of Key Pipeline Drugs
    • 10.1.1. Indolent NHL
    • 10.1.2. Aggressive NHL
  • 10.2. Commercial Benchmarking of Key Pipeline Drugs
  • 10.3. Competitive Assessment
  • 10.4. Top-Line, 10-Year Forecast
    • 10.4.1. US
    • 10.4.2. 5EU
    • 10.4.3. Japan

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. NHL Patient Population Segmentation
    • 11.4.2. Percentage of Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic and Biosimilar Erosion
  • 11.5. Primary Research
    • 11.5.1. Physicians and Specialists Included in This Study
    • 11.5.2. Online Survey of High Prescribing Physicians
  • 11.6. About the Authors
    • 11.6.1. Analyst
    • 11.6.2. Epidemiologist
    • 11.6.3. Therapy Area Director
    • 11.6.4. Global Director of Therapy Analysis and Epidemiology
    • 11.6.5. Global Head of Healthcare
  • 11.7. About GlobalData
  • 11.8. Disclaimer

List of Tables

  • Table 1: Non-Hodgkin's Lymphoma Subtypes
  • Table 2: Symptoms of Non-Hodgkin's Lymphoma
  • Table 3: The Ann Arbor Staging System and the Cotswold Modifications for NHL
  • Table 4: Molecular Characteristics of Non-Hodgkin's Lymphoma (2008 WHO Classification)
  • Table 5: Treatment Guidelines for Non-Hodgkin's Lymphoma in the 7MM
  • Table 6: Risk Factors and Comorbidities for NHL
  • Table 7: US, Age- and Sex-Specific Incidence of B-Cell NHL During 2001-2010
  • Table 8: 7MM, Sources of B-Cell NHL Incidence Data
  • Table 9: 7MM, Incident Cases of Follicular Lymphoma, Ages ≥30 Years, Both Sexes, N, Selected Years 2014-2024
  • Table 10: 7MM, Age-Specific Incident Cases of Follicular Lymphoma, Both Sexes, N (Row %), 2014
  • Table 11: 7MM, Sex-Specific Incident Cases of Follicular Lymphoma, Ages ≥30 Years, N (Row %), 2014
  • Table 12: 7MM, Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, Both Sexes, N, Selected Years 2014-2024
  • Table 13: 7MM, Age-Specific Incident Cases of Marginal Zone Lymphoma, Both Sexes, N (Row %), 2014
  • Table 14: 7MM, Sex-Specific Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, N (Row %), 2014
  • Table 15: 7MM, Incident Cases of DLBCL, Ages ≥30 Years, Both Sexes, N, Selected Years, 2014-2024
  • Table 16: 7MM, Age-Specific Incident Cases of DLBCL, Both Sexes, N (Row %), 2014
  • Table 17: 7MM, Sex-Specific Incident Cases of DLBCL, Ages ≥30 Years, N (Row %), 2014
  • Table 18: 7MM, Incident Cases of Mantle Cell Lymphoma, Ages ≥30 Years, Both Sexes, N, Selected Years 2014-2024
  • Table 19: 7MM, Age-Specific Incident Cases of Mantle Cell Lymphoma, Both Sexes, N (Row %), 2014
  • Table 20: 7MM, Sex-Specific Incident Cases of Mantle Cell Lymphoma, Ages ≥30 Years, N (Row %), 2014
  • Table 21: Leading Treatments for NHL Patients in the 7MM
  • Table 22: Product Profile - Imbruvica
  • Table 23: Efficacy of Imbruvica in MCL
  • Table 24: Efficacy of Imbruvica in FL
  • Table 25: Efficacy of Imbruvica in DLBCL
  • Table 26: Safety of Imbruvica in MCL
  • Table 27: Imbruvica SWOT Analysis, 2015
  • Table 28: Product Profile - Revlimid
  • Table 29: Efficacy of Revlimid in MCL
  • Table 30: Efficacy of Revlimid in DLBCL
  • Table 31: Efficacy of Revlimid in DLBCL
  • Table 32: Safety of Revlimid
  • Table 33: Revlimid SWOT Analysis, 2015
  • Table 34: Product Profile - Rituxan
  • Table 35: Efficacy of Rituxan
  • Table 36: Safety of Rituxan
  • Table 37: Rituxan SWOT Analysis, 2015
  • Table 38: Product Profile - Treanda
  • Table 39: Efficacy of Treanda
  • Table 40: Safety of Treanda
  • Table 41: Treanda SWOT Analysis, 2015
  • Table 42: Product Profile - Velcade
  • Table 43: Efficacy of Velcade
  • Table 44: Safety of Velcade
  • Table 45: Velcade SWOT Analysis, 2015
  • Table 46: Product Profile - Zevalin
  • Table 47: Efficacy of Zevalin
  • Table 48: Safety of Zevalin
  • Table 49: Zevalin SWOT Analysis, 2015
  • Table 50: Product Profile - Zydelig
  • Table 51: Efficacy of Zydelig
  • Table 52: Safety of Zydelig
  • Table 53: Zydelig SWOT Analysis, 2015
  • Table 54: Overall Unmet Needs - Current Level of Attainment
  • Table 55: Key Products in the Present and Future B-Cell NHL Market, 2015
  • Table 56: Design of Current Registration Trials in Indolent B-Cell NHL
  • Table 57: Design of Current Registration Trials in Aggressive B-Cell NHL
  • Table 58: Non-Hodgkin's Lymphoma - Late-Stage Pipeline, 2015
  • Table 59: Product Profile - Afinitor
  • Table 60: Efficacy of Afinitor in DLBCL
  • Table 61: Safety of Afinitor in DLBCL
  • Table 62: Afinitor SWOT Analysis, 2015
  • Table 63: Product Profile - Arzerra
  • Table 64: Efficacy of Arzerra in FL
  • Table 65: Safety of Arzerra in FL
  • Table 66: Arzerra SWOT Analysis, 2015
  • Table 67: Product Profile - Copanlisib
  • Table 68: Efficacy of Copanlisib
  • Table 69: Safety of Copanlisib
  • Table 70: Copanlisib SWOT Analysis, 2015
  • Table 71: Product Profile - Duvelisib
  • Table 72: Efficacy of Duvelisib
  • Table 73: Safety of Duvelisib
  • Table 74: Duvelisib SWOT Analysis, 2015
  • Table 75: Product Profile - Gazyva
  • Table 76: Efficacy of Gazyva in Indolent NHL
  • Table 77: Efficacy of Gazyva in DLBCL
  • Table 78: Safety of Gazyva
  • Table 79: Safety of Gazyva in DLBCL
  • Table 80: Gazyva SWOT Analysis, 2015
  • Table 81: Product Profile - Opdivo
  • Table 82: Efficacy of Opdivo
  • Table 83: Safety of Opdivo
  • Table 84: Opdivo SWOT Analysis, 2015
  • Table 85: Early-Stage Pipeline Products in Non-Hodgkin's Lymphoma
  • Table 86: Clinical Benchmarking of Key Marketed and Pipeline Drugs - Indolent NHL, First-Line Therapies, 2015
  • Table 87: Clinical Benchmarking of Key Marketed and Pipeline Drugs - Indolent NHL, Relapsed/Refractory Therapies, 2015
  • Table 88: Clinical Benchmarking of Key Marketed and Pipeline Drugs - Indolent NHL, Consolidation/Maintenance Therapies, 2015
  • Table 89: Clinical Benchmarking of Key Marketed and Pipeline Drugs - Aggressive NHL, First-Line Therapies, 2015
  • Table 90: Clinical Benchmarking of Key Marketed and Pipeline Drugs - Aggressive NHL, Relapsed/Refractory Therapies, 2015
  • Table 91: Clinical Benchmarking of Key Marketed and Pipeline Drugs - Aggressive NHL, Consolidation/Maintenance Therapies, 2015
  • Table 92: Commercial Benchmarking of Key Marketed and Pipeline Drugs - NHL, 2015
  • Table 93: Commercial Benchmarking of Key Marketed and Pipeline Drugs - NHL, 2015 (continued from Table 93)
  • Table 94: Top-Line Sales Forecasts ($bn) for NHL, 2014-2024
  • Table 95: Key Events Impacting Sales for NHL in the 7MM, 2014-2024
  • Table 96: NHL Market in the US and 5EU - Drivers and Barriers, 2015
  • Table 97: NHL Patient Population Segmentations in the 7MM - Secondary Sources
  • Table 98: Patient Populations Targeted by NHL Marketed and Pipeline Drug Developers
  • Table 99: NHL Marketed and Pipeline Products Broken Down by Therapeutic Class
  • Table 100: Key Branded Drug Key Launch Dates and Patent Expiries for NHL in the 7MM
  • Table 101: Key Generic and Biosimilar Entry Dates for NHL in the 7MM
  • Table 102: High-Prescribing Physicians Surveyed by Country

List of Figures

  • Figure 1: Common Follicular Lymphoma Drug Treatment Options by Line of Therapy in the 7MM, 2015
  • Figure 2: Common Marginal Zone Lymphoma Drug Treatment Options by Line of Therapy in the 7MM, 2015
  • Figure 3: Common Diffuse Large B-Cell Lymphoma Drug Treatment Options by Line of Therapy in the 7MM, 2015
  • Figure 4: Common Mantle Cell Lymphoma Drug Treatment Options by Line of Therapy in the 7MM, 2015
  • Figure 5: 7MM, Incident Cases of Follicular Lymphoma, Ages ≥30 Years, Both Sexes, N, 2014-2024
  • Figure 6: 7MM, Age-Specific Incident Cases of Follicular Lymphoma, Ages ≥30 Years, Both Sexes, N, 2014
  • Figure 7: 7MM, Sex-Specific Incident Cases of Follicular Lymphoma, Ages ≥30 Years, N, 2014
  • Figure 8: 7MM, Age-Standardized Incidence of Follicular Lymphoma (Cases per 100,000 Population), Ages ≥30 Years, by Sex, 2014
  • Figure 9: 7MM, Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, Both Sexes, N, 2014-2024
  • Figure 10: 7MM, Age-Specific Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, Both Sexes, N, 2014
  • Figure 11: 7MM, Sex-Specific Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, N, 2014
  • Figure 12: 7MM, Age-Standardized Incidence of Marginal Zone Lymphoma (Cases per 100,000 Population), Ages ≥30 Years, by Sex, 2014
  • Figure 13: 7MM, Incident Cases of DLBCL, Ages ≥30 Years, Both Sexes, N, 2014-2024
  • Figure 14: 7MM, Age-Specific Incident Cases of DLBCL, Ages ≥30 Years, Both Sexes, N, 2014
  • Figure 15: 7MM, Sex-Specific Incident Cases of DLBCL, Ages ≥30 Years, N, 2014
  • Figure 16: 7MM, Age-Standardized Incidence of DLBCL (Cases per 100,000 Population), Ages ≥30 Years, by Sex, 2014
  • Figure 17: 7MM, Incident Cases of Mantle Cell Lymphoma, Ages ≥30 Years, Both Sexes, N, 2014-2024
  • Figure 18: 7MM, Age-Specific Incident Cases of Mantle Cell Lymphoma, Both Sexes, N, 2014
  • Figure 19: 7MM, Sex-Specific Incident Cases of Mantle Cell Lymphoma, Ages ≥30 Years, N, 2014
  • Figure 20: 7MM, Age-Standardized Incidence of Mantle Cell Lymphoma (Cases per 100,000 Population), Ages ≥30 Years, by Sex, 2014
  • Figure 21: Imbruvica - Ongoing Clinical Trials in B-Cell NHL
  • Figure 22: Revlimid - Ongoing Clinical Trials in B-Cell NHL
  • Figure 23: Velcade - Ongoing Clinical Trials in B-Cell NHL
  • Figure 24: Zydelig - Ongoing Clinical Trials in B-Cell NHL
  • Figure 25: Afinitor - Phase III Trial in Aggressive B-Cell NHL
  • Figure 26: Arzerra - Phase II and III Trials in Indolent and Aggressive NHL
  • Figure 27: Copanlisib - Phase II and III Trials in Indolent and Aggressive NHL
  • Figure 28: Duvelisib - Phase II and III Trials in Indolent NHL
  • Figure 29: Gazyva - Phase II and III Trials in Indolent and Aggressive NHL
  • Figure 30: Opdivo - Phase II Trials in Indolent and Aggressive NHL
  • Figure 31: Competitive Assessment of the Key Marketed and Late-Stage Pipeline Agents in Indolent NHL, 2014-2024
  • Figure 32: Competitive Assessment of the Key Marketed and Late-Stage Pipeline Agents in Aggressive NHL, 2014-2024
Back to Top